Mosapride as a Pre-endoscopy Preparation in a Patient Receiving GLP-1 Receptor Agonist Therapy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
We present the case of a 66-year-old man who underwent upper gastrointestinal endoscopy and developed significant gastric residue after treatment with a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) for type 2 diabetes. Despite prolonged fasting, large volumes of gastric residue persisted, thus impairing mucosal visualization. Instead of discontinuing GLP-1RA therapy, mosapride citrate was introduced as a gastroprokinetic agent. Three days before endoscopy, the patient received mosapride, which resulted in complete gastric clearance and optimal endoscopic visualization. This case suggests that mosapride may be an effective pre-endoscopic preparation to counteract GLP-1RA-induced delayed gastric emptying.
Fields of Study & Subjects
Gastrointestinal motility and disorders
Diabetes Treatment and Management
Gastrointestinal Bleeding Diagnosis and Treatment
Publication details
- Journal / source
- Internal Medicine
- Volume
- 65
- Issue
- 22
- Pages
- 2994–2997
- Publication date
- 30 March 2026
- Language
- EN